FP6Индивидуална стипендия2007–2010

MYO-PATHOGENESIS · Gene discovery and disease pathogenesis in the inherited myopathies

6РП — Действия „Мария Кюри“

Период
2007-05-01 → 2010-04-30
Финансиране от ЕС
204 966 €
Участници
2
Схема
OIF

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Генетичните причини за наследствените миопатии се проучват чрез търсене на нови мутации, като например в гена LARGE. Това помага за разбирането на механизмите, които водят до мускулна слабост, дихателна недостатъчност и загуба на мобилност при пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Final Activity Report Summary - MYO-PATHOGENESIS (Gene discovery and disease pathogenesis in the inherited myopathies.)

The inherited myopathies are a diverse group of disorders resulting in significant morbidity, and hence significant health care costs, due to loss of mobility and respiratory failure. There is a wide spectrum of clinical severity, ranging from death in the newborn period, through to adult onset cases with slow progression of weakness. The ‘congenital myopathies’ are usually defined on morphological grounds, based on the presence of distinctive changes in the muscle fibre. This group includes nemaline myopathy, central core disease, congenital fibre type disproportion (CFTD), multiminicore disease, myotubular myopathy and SEPN1-related myopathy. Mutations in the selenoprotein N gene (SEPN1) lead to at least four congenital myopathies that are grouped under the name ‘SEPN1-related myopathy’. These congenital myopathies were originally considered to be separate entities based on their histological characteristics, even though patients shared the common clinical phenotype of weakness of axial muscles leading to respiratory insufficiency and generalised atrophy. A large number of disease genes were identified for the inherited myopathies over the last 10 years or so. The laboratories of Drs North and Guicheney played an internationally leading role in many of these gene discoveries and had an extensive collection of patient diagnostic specimens for further gene discovery projects. The first aim of my project was to investigate the genetic basis of inherited myopathies through identification of novel genes or molecular mechanisms. I participated in the identification of a large duplication and deletion in the LARGE gene of two sisters presenting moderate mental retardation and cerebellar malformations together with dystrophic changes and markedly reduced alpha-dystroglycan glycosylation staining on muscle biopsy. We identified, along with a colleague, the size of the duplication, searched for its intronic location and the breakpoints and found a more complex rearrangement than initially thought which was associated with an intronic deletion. The second aim of my project was to explore pathogenetic mechanisms of weakness in inherited myopathies. During my fellowship, I worked on four main diseases, namely nemaline myopathy and mitochondrial disorders, congenital fiber type disproportion (CFTD) and selenoprotein N related myopathies. Through the application of different techniques of physiology, cellular and molecular biology I was able to explore the different mechanisms underlying these pathologies. This research had an immediate application to clinical practice in term of diagnostic accuracy, genetic counselling and prenatal diagnosis. This work also provided new and important information concerning normal skeletal biology and disease pathogenesis as the basis for the development of specific therapies. My work during these three years led to the publication of one first author paper and two co-author papers in international peer-reviewed journals. Another co-author paper was submitted and two others were in preparation by the time of the project completion. I finally presented my work during seven international congresses either by oral communications or by poster.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The proposed project for Dr Aurélie Vandebrouck builds upon discoveries in the Institute for Neuromuscular Research (INMR) and Institut de Myologie (IM) and is designed to take advantage of the existing collaboration between the two centres, the unique resources of DNA and muscle samples collected over the past decade, and the expertise available in the two centres in gene discovery, production of mutant proteins, tissue culture and animal models.Researchers in both Institutions, and others, have identified disease genes for inherited myopathies. Nevertheless, many disease genes remain to be identified, and the pathobiology of the identified mutations remains largely obscure.In this project, Dr Vandebrouck will contribute to the gene discovery work and investigate further the molecular mechanisms resulting in muscle weakness observed in inherited myopathies. Inherited myopathies are a diverse group of muscle disorders due to mutations in different genes.The study will focus principally on the identification of new disease genes and the study of mechanisms underlying muscle weakness for inherited congenital myopathies: particularly nemaline myopathy, congenital fibre type disproportion, and central core disease.This research will have immediate application to clinical practice in terms of diagnostic accuracy, genetic counselling and prenatal diagnosis. In addition, it will provide new and important information concerning normal skeletal muscle biology and disease pathogenesis, as the basis for the development of specific therapies.

Оригинален текст от CORDIS (на английски).

Участници

  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · PARISКоординаторФранция
  • THE CHILDREN'S HOSPITAL AT WESTMEAD (THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN) · WESTMEADНиво градАвстралия

Връзки

Данни: CORDIS, © Европейски съюз